Rein Therapeutics has announced a collaboration with imaging analytics company Qureight to incorporate its deep-learning platform into the planned Phase 2 clinical trial of LTI-03, a novel investigational treatment for idiopathic pulmonary fibrosis (IPF).

The partnership aims to enhance analysis of lung imaging and biomarker data, potentially supporting a deeper understanding of the drug’s mechanism in patients with this progressive lung condition.

The trial will evaluate the safety, tolerability, and biological effects of LTI-03—a multi-pathway Caveolin-1-related peptide—following promising Phase 1b results. In the earlier study, seven of eight biomarkers showed a positive trend, with dose-dependent effects and statistically significant changes seen in several markers.

Qureight will provide full end-to-end imaging core lab services, including site qualification, quality control, data handling, and AI-powered image analysis. The deep-learning platform will measure fibrotic, vascular, and airway lung compartments to detect volumetric changes that may correlate with LTI-03 activity across biomarkers. This quantitative approach is expected to improve trial efficiency and reduce interpretation time, which could accelerate the study timeline.

“In our Phase 1b clinical trial of LTI-03, we emphasized the importance of biomarkers for measuring progress in patients with IPF treated with LTI-03 as well as for illustrating the dual mechanism of LTI-03 in the body,” said Dr Brian Windsor, CEO of Rein Therapeutics. “We are taking the evaluation of biomarkers a step further with the application of cutting-edge deep-learning imaging technology and detailed AI-based data analysis by collaborating with Qureight on this Phase 2 trial.”

Qureight’s CEO, Dr Muhunthan Thillai, added: “Our AI tools will provide precise, quantitative insights into how LTI-03 affects lung structure and function. This partnership represents another milestone in accelerating fibrotic lung disease treatment, which is so desperately needed for patients.”

The use of AI in respiratory trials has grown in recent years as developers seek more sensitive, objective endpoints—especially in conditions like IPF, where disease progression can be subtle and variable.

Rein plans to release further details on the Phase 2 trial design in the near term.